ImmunIC, Inc. (IMUX) is a clinical-stage biopharmaceutical company with a mission to formulate and develop a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company, originally based in Germany, was founded in 2016 by seasoned drug developers and scientists in the therapeutic area of immunology.
The focus of IMUX is to develop oral treatments that target the immune system, allowing it to handle chronic inflammatory and autoimmune conditions more effectively. These conditions include diseases like Crohn’s disease, ulcerative colitis, and psoriasis, among others.
ImmunIC, Inc.’s primary clinical assets include IMU-838, which is an orally available, next-generation selective immune modulator designed to inhibit an enzyme called dihydroorotate dehydrogenase (DHODH). IMU-838 has demonstrated the potential to debilitate harmful immune cell proliferation without disturbing other nutrient-relevant cells.
The company also has other active product candidates in clinical and pre-clinical development, such as IMU-935 and IMU-856. Each of these candidates is being carefully designed and evaluated for its potential in treating various severe autoimmune and inflammatory conditions.
In comparison to biologics or standard of care therapies, IMUX's oral therapies present advantages such as direct targeting of inflamed tissue, fewer side effects due to cell selectivity, and easier administration. This targeted and selective approach forms the foundation of the company’s research and development efforts.
Besides a strong dedication to research and development, the company places a high priority on collaboration and partnerships, both academically and industrially. The company's approach is to balance in-house research with external collaborations to drive scientific innovation and advancement.
ImmunIC, Inc. trades in the NASDAQ stock market under the ticker IMUX, reflecting a marked presence in the U.S. capital markets. It has come into the spotlight amongst investors, buoyed by positive findings in various clinical trials and growing recognition for its innovative approach towards tackling debilitating diseases.
The firm maintains a commitment to patient well-being at the core of its mission and places immense value on the quality of its investigative work. With robust technology and streamlined evaluation methods, IMUX's promising drug pipeline is improving the lives of individuals suffering from chronic inflammatory and autoimmune diseases by harnessing the power of the body's own immune system.